27th November 2018
- 0 comments
OMass Therapeutics, a biopharmaceutical company using structural mass spectrometry to discover novel medicines, has announced completion of a £14 million Series A financing. New investor Syncona Ltd led the round, alongside Oxford Sciences Innovation. The financing supports development of a pipeline of drug development programmes.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.